Efficacy of an Encapsulated Probiotic Bifidobacterium Infantis 35624 in Irritable Bowel Syndrome

PHASE3CompletedINTERVENTIONAL
Enrollment

362

Participants

Timeline

Start Date

January 31, 2004

Primary Completion Date

September 30, 2004

Study Completion Date

September 30, 2004

Conditions
Irritable Bowel Syndrome
Interventions
DRUG

Bifidobacterium infantis 35624

Trial Locations (20)

BS15 2NJ

The Orchard Medical Centre, Bristol

PE7 3JL

Yaxley Group Practice, The Health Centre, Peterborough

CB7 5JD

The Staploe Medical Centre, Soham

PE8 6PL

Wansford Surgery, Wansford

BT38 8TP

Old School Surgery, Greenisland

BT19 1PP

Springhill Surgery, Bangor

BT30 6HY

Downpatrick Health Centre, Downpatrick

TN39 5JB

Little Common Surgery, Bexhill-on-Sea

TN40 1JJ

Sea Road Surgery, Bexhill-on-Sea

KY 12 8SJ

Valleyfield Health Centre, High Valleyfield

TW18 1SL

Stanwell Road Surgery, Ashford

HA3 7LT

Belmont Health Centre, Harrow

BA11 1EZ

The Frome Medical Practice, Frome

DN1 2EG

The Burns Practice, Doncaster

S3 9DA

The Burngreave Surgery, Sheffield

KT 24 6QT

The Medical Centre, East Horsley

CF23 5SY

The Penylan Surgery, Cardiff

CV32 4RA

Sherbourne Medical Centre, Royal Leamington Spa

SN15 1HP

Hathaway Surgery, Chippenham

SN25 4YZ

Swindon Medical Research Centre, Abbeymeads Medical, Swindon

All Listed Sponsors
collaborator

Alimentary Health Ltd

INDUSTRY

lead

Procter and Gamble

INDUSTRY

NCT00135031 - Efficacy of an Encapsulated Probiotic Bifidobacterium Infantis 35624 in Irritable Bowel Syndrome | Biotech Hunter | Biotech Hunter